{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-005040","form_type":"8-K","ticker":"BOLT","cik":"0001641281","company_name":"Bolt Biotherapeutics, Inc.","filed_at":"2022-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.516301+00:00","generated_at":"2026-06-26T13:37:15.327761+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Bolt Biotherapeutics reports 2021 results; cash $271.6M, BDC-1001 on track for RP2D in 2022","bullets":["Cash, cash equivalents, and marketable securities $271.6M at Dec 31, 2021 vs $22.8M at end 2020; runway into 2024.","Collaboration revenue $1.3M for FY 2021 from Genmab R&D collaboration (vs $0.2M in 2020).","R&D expenses $75.7M, G&A $18.4M; operating loss $92.8M for FY 2021.","BDC-1001 (HER2) Phase 1/2 on track for recommended Phase 2 dose in 2022; Opdivo combo arm dosed first patient Dec 2021.","Preclinical data on BDC-2034, BDC-3042, and PD-L1 ISAC to be presented at AACR 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-005040","json":"https://secwatch.observer/filing/0000950170-22-005040.json","markdown":"https://secwatch.observer/filing/0000950170-22-005040.md","text":"https://secwatch.observer/filing/0000950170-22-005040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641281/000095017022005040/0000950170-22-005040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641281/000095017022005040/bolt-20220330.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T13:37:15.327761+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}